Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Abstract

Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs (NCT04940299, NCT03999749).

References

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Estelle Bettelli, Yijun Carrier, Wenda Gao, Nature Developmental BiologyAutoimmune DiseaseLymphocyte DevelopmentImmune Cell DevelopmentAdaptive Immune System	2006	6.8K
The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells Ivaylo I. Ivanov, Brent S. McKenzie, Liang Zhou, Cell InflammationCytokineLymphocyte DevelopmentImmune RegulationImmunology	2006	5K
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2016	3.7K
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, The Lancet Oncology Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor	2015	2.6K
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert, Antoni Ribas, Jedd D. Wolchok, The Lancet OncologyMedicineIpilimumab-refractory Advanced MelanomaImmunologyMelanoma	2014	1.7K
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Journal of Clinical Oncology	2021	1.7K
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, New England Journal of Medicine	2018	1.3K
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, The Lancet Oncology MedicineMetronomic TherapyPathologyCancer TreatmentOncology	2016	1.2K

Page 1